Astellas Pharma Inc. (OTCMKTS:ALPMY) Sees Large Decrease in Short Interest

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the target of a significant decrease in short interest in December. As of December 31st, there was short interest totalling 31,500 shares, a decrease of 58.7% from the December 15th total of 76,200 shares. Based on an average trading volume of 787,700 shares, the short-interest ratio is currently 0.0 days.

Astellas Pharma Trading Up 0.6 %

Shares of Astellas Pharma stock opened at $9.54 on Wednesday. The stock has a market capitalization of $17.26 billion, a PE ratio of 45.43 and a beta of 0.34. Astellas Pharma has a 52 week low of $9.15 and a 52 week high of $13.14. The stock has a 50 day moving average price of $10.14 and a two-hundred day moving average price of $11.02. The company has a debt-to-equity ratio of 0.26, a quick ratio of 0.72 and a current ratio of 0.90.

Astellas Pharma (OTCMKTS:ALPMY) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $0.13 earnings per share (EPS) for the quarter. The business had revenue of $3.11 billion during the quarter. Astellas Pharma had a net margin of 3.26% and a return on equity of 10.33%. As a group, equities analysts anticipate that Astellas Pharma will post 0.61 earnings per share for the current fiscal year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.